MacroGenics (MGNX) vs ProQR Therapeutics N.V. (PRQR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
MacroGenics (MGNX) has outperformed ProQR Therapeutics N.V. (PRQR) over the past year, gaining 99.4% versus a loss of 33.5%. Over five years, PRQR leads with a -80.1% price change compared with -82.0% for MGNX. MacroGenics is the larger company by market cap ($238.2 million vs $230.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MGNX | PRQR |
|---|---|---|
| Share price | $3.74 | $1.63 |
| Market cap | $238.24M | $230.02M |
| 1-day change | +5.35% | +3.82% |
| YTD return | +120.50% | -22.28% |
| 1-year return | +99.44% | -33.47% |
| 5-year return | -82.02% | -80.08% |
| EPS (TTM) | $-1.70 | $-0.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.08 | $3.10 |
| 52-week low | $1.29 | $1.33 |
| Distance from 52-week high | -26.38% | -47.42% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +113.90% | +377.30% |
| Average volume | 622.92K | 796.41K |
| Shares outstanding | 63.70M | 141.12M |
| Employees | 293 | 186 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MGNX has outperformed PRQR by 132.9 percentage points over the past year.
About MacroGenics
MGNX stock →MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials.
Health Care · Biotechnology: Pharmaceutical Preparations · 293 employees
About ProQR Therapeutics N.V.
PRQR stock →ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs.
Health Care · Biotechnology: Pharmaceutical Preparations · 186 employees
MGNX vs PRQR FAQ
Which is bigger, MacroGenics or ProQR Therapeutics N.V.?
MacroGenics (MGNX) is larger, with a market capitalization of $238.24M compared with $230.02M for ProQR Therapeutics N.V. (PRQR).
Which stock has performed better over the past year, MGNX or PRQR?
MGNX returned +99.44% over the past 12 months, compared with -33.47% for PRQR (price return, excluding dividends). Past performance does not predict future results.
Are MacroGenics and ProQR Therapeutics N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.